Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Ryo, Ito"'
Autor:
Shinji Uemoto, Masahito Ogura, Nobuya Inagaki, Junji Fujikura, Hirofumi Noguchi, Takayuki Anazawa, Ryo Ito, Toshihiro Nakamura, Hideaki Okajima
Publikováno v:
Journal of Diabetes Investigation, Vol 11, Iss 6, Pp 1677-1680 (2020)
Journal of Diabetes Investigation
Journal of Diabetes Investigation
To date, studies of patients with islet transplantation addressing intermittently scanned continuous glucose monitoring profile and the flexibility of the graft islet function under different doses of insulin administration, both of which reflect the
Autor:
Takayuki Anazawa, Nobuya Inagaki, Junji Fujikura, Masahito Ogura, Hideaki Okajima, Ryo Ito, Toshihiro Nakamura, Shinji Uemoto
Publikováno v:
Journal of Diabetes Investigation, Vol 11, Iss 2, Pp 363-372 (2020)
Journal of Diabetes Investigation
Journal of Diabetes Investigation
Aims/Introduction To investigate the long‐term efficacy and safety of islet transplantation (ITx) compared with multiple daily injections (MDI) or continuous subcutaneous insulin infusion (CSII). Materials and Methods Among 619 patients diagnosed a
Autor:
Taisuke Mochida, Noriko Tsubooka-Yamazoe, Hideyuki Hiyoshi, Hikaru Ueno, Hirokazu Matsumoto, Ryo Ito, Taro Toyoda
Publikováno v:
Diabetes. 69(4)
The host environment is a crucial factor for considering the transplant of stem cell–derived immature pancreatic cells in patients with type 1 diabetes. Here, we investigated the effect of insulin (INS)-deficient diabetes on the fate of immature pa
Autor:
Mitsugi Ookawara, Koji Takeuchi, Yusuke Moritoh, Hitomi Ogino, Tomoki Yoshihara, Masanori Watanabe, Shin-ichi Abe, Yoshimasa Ishimura, Ryo Ito, Yoshiyuki Tsujihata, Hirohisa Miyashita, Yasufumi Miyamoto, Nobuhiro Nishigaki, Hikaru Ueno, Yukio Yamada
Publikováno v:
Diabetes. 68
GPR40/FFAR1 is a G-protein-coupled receptor expressed in pancreatic islets and enteroendocrine cells. SCO-267 is a novel full agonist of GPR40 being developed as a treatment for type 2 diabetes and obesity. The efficacy of SCO-267 was investigated in
Autor:
Nobuhiro Nishigaki, Hikaru Ueno, Yasufumi Miyamoto, Hirohisa Miyashita, Koji Takeuchi, Yoshiyuki Tsujihata, Minoru Maruyama, Ryo Ito, Hitomi Ogino, Yusuke Moritoh, Shin-ichi Abe
Publikováno v:
PLoS ONE, Vol 14, Iss 9, p e0222653 (2019)
PLoS ONE
PLoS ONE
GPR40/FFAR1 is a Gq protein-coupled receptor expressed in pancreatic β cells and enteroendocrine cells, and mediates insulin and incretin secretion to regulate feeding behavior. Several GPR40 full agonists have been reported to reduce food intake in
Autor:
Hitomi Ogino, Tsuyoshi Maekawa, Masanori Watanabe, Mitsugi Ookawara, Koji Takeuchi, Yusuke Moritoh, Hirohisa Miyashita, Hikaru Ueno, Akihiro Kobayashi, Shin-ichi Abe, Nobuhiro Nishigaki, Tomoki Yoshihara, Yukio Yamada, Yoshiyuki Tsujihata, Ryo Ito, Yasufumi Miyamoto
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 370(2)
The GPR40/FFA1 receptor is a G-protein-coupled receptor expressed in the pancreatic islets and enteroendocrine cells. Here, we report the pharmacological profiles of (3S)-3-cyclopropyl-3-{2-[(1-{2-[(2,2-dimethylpropyl)(6-methylpyridin-2-yl)carbamoyl]
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 357:217-227
Sulfonylureas (SUs) are widely used insulin secretagogues, but they have adverse effects including hypoglycemia and secondary failure. Fasiglifam/TAK-875, a selective GPR40 agonist, enhances glucose-stimulated insulin secretion and improves hyperglyc
Autor:
Tsuneo Yasuma, Ryo Ito, Masami Suzuki, Koji Takeuchi, Ayako Harada, Yoshiyuki Tsujihata, Yu Momose, Nobuyuki Negoro
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 339:228-237
G protein-coupled receptor 40/free fatty acid receptor 1 (GPR40/FFA(1)) is highly expressed in pancreatic β cells and mediates free fatty acid-induced insulin secretion. This study examined the pharmacological effects and potential for avoidance of
Autor:
Kazumasa Miyawaki, Kae Matsuda-Nagasumi, Koji Takeuchi, Yugo Habata, Hidetoshi Komatsu, Chiori Yabuki, Risa Maeda, Naoya Kikuchi, Kensuke Sakuma, Yoshiyuki Tsujihata, Masaaki Mori, Ryo Ito
Publikováno v:
PLoS ONE, Vol 8, Iss 10, p e76280 (2013)
PLoS ONE
PLoS ONE
Selective free fatty acid receptor 1 (FFAR1)/GPR40 agonist fasiglifam (TAK-875), an antidiabetic drug under phase 3 development, potentiates insulin secretion in a glucose-dependent manner by activating FFAR1 expressed in pancreatic β cells. Althoug
Autor:
Masami Suzuki, Koji Takeuchi, Naoyuki Kanzaki, Tomoyuki Odani, Nobuhiro Suzuki, Yoshiyuki Tsujihata, Tsuneo Yasuma, Shinichiro Matsunaga, Masami Nonaka, Satoshi Mikami, Yu Momose, Takashi Santou, Shinobu Sasaki, Miyuki Funami, Junichi Miyazaki, Ryo Ito, Akio Morohashi, Nobuyuki Negoro, Masahiro Ito
Publikováno v:
Journal of medicinal chemistry. 55(8)
G protein-coupled receptor 40 (GPR40)/free fatty acid receptor 1 (FFA1) is a free fatty acid (FFA) receptor that mediates FFA-amplified glucose-stimulated insulin secretion in pancreatic β-cells. We previously identified (2,3-dihydro-1-benzofuran-3-